

DATASET BRIEF

Surface proteomic analysis of differentiated versus stem-like osteosarcoma human cells

Marica Gemei¹, Claudia Corbo¹, Francesca D'Alessio¹, Rosa Di Noto^{1,2}, Renza Vento³ and Luigi Del Vecchio^{1,2}

¹ CEINGE-Biotecnologie Avanzate s.c.a.r.l., Napoli, Italy

² Dipartimento di Medicina molecolare e Biotecnologie mediche, Università "Federico II" di Napoli, Napoli, Italy

³ Dipartimento di Scienze Biomediche, Università Degli Studi di Palermo, Policlinico, Palermo, Italy

Cancer stem cell characterization represents a breakthrough in cancer research. Despite evidence showing the existence and the role of cancer stem cells in osteosarcoma (OS) onset and progression, little is known about their specific surface phenotype. To address this issue, we carried out a cytometric analysis with an antibody-array comprising 245 membrane proteins comparing the stem and differentiated OS cells. As experimental model, we chose the stem-like cell line 3aminobenzamide-OS and its parental, differentiated, cell line MG63. We identified 50 differentially expressed, 23 homogeneously expressed, and 172 not expressed proteins in the two cell line models, thus defining a surface protein signature specific for each of them. Furthermore, we selected ERK1/2 (p44/42 mitogen-activated protein kinases) as a potential pathway correlated with processes that characterize tumorigenic potential and stemness of 3aminobenzamide-OS cells.

Received: May 2, 2013

Revised: July 23, 2013

Accepted: August 21, 2013

Keywords:

Cancer stem cell / Cell biology / Osteosarcoma / Surface proteome



Additional supporting information may be found in the online version of this article at the publisher's web-site

Osteosarcoma (OS) is the most frequent nonhematologic form of primary bone cancer in children and young adults, accounting for about 15–20% of all bone tumors [1, 2]. It is a devastating malignant neoplasm arising from primitive transformed cells of mesenchymal origin exhibiting osteoblastic differentiation and that produces malignant osteoids [3]. Due to the aggressive malignant potential and early metastasis, OS is a disease with a low long-term survival rate and a poor early diagnosis. In fact, despite important progresses in surgery,

radiotherapy and neoadjuvant chemotherapy, the morbidity of OS has been increased by 1.4% per year in the past 25 years [4, 5]. Increasing evidence suggests that tumors are organized in a hierarchy of heterogeneous cell populations, with the capability to sustain tumor formation and growth residing specifically in a small subset of cells, that is, the cancer stem cells (CSCs) [6–8]. These cells are endowed with both self-renewal and multilineage differentiation potential; they induce cell proliferation, invasion, and metastasis. Despite it is still unclear whether a CSC originates from transformed organ stem cells or whether it acquires the self-renewal capability during tumorigenic transformation, the existence of CSC and their role of "source" for tumor maintenance/growth is today widely accepted. CSCs confer resistance to therapies; thus, a successful cure of cancer should require CSCs eradication. Therefore, a number of recent studies have been focused on CSCs existence revelation and/or on the understanding of their features and molecular mechanisms in the attempt to

Correspondence: Dr. Marica Gemei, CEINGE Biotecnologie Avanzate s.c.a.r.l., Via Gaetano Salvatore 486, (ex Comunale Margherita, 482), 80145, Napoli, Italia

E-mail: maricagemei@gmail.com

Fax: +390813737808

Abbreviations: **3-AB**, 3-aminobenzamide; **CD**, cluster of differentiation; **CSC**, cancer stem cell; **ERK**, extracellular signal-regulated kinase; **IPA**, ingenuity pathway analysis; **MAPK**, p44/42 mitogen-activated protein kinases; **OS**, osteosarcoma; **PAK**, p21-activated kinase; **PTEN**, phosphatase and tensin homologue deleted on chromosome 10

Colour Online: See the article online to view Fig. 1 in colour.

Table 1. Surface proteins differentially expressed in 3AB-OS and MG63 cells. Percentages of positive cells are reported for both cell lines

Antigen	Gene symbol	3AB-OS	MG63
CD1b	CD1b	2.0	bdl
CD10	CALLA	8.9	bdl
CD30	TNFRSF8	83.8	bdl
CD32	FCGR2A	0.7	bdl
CD49a	ITGA1	67.8	bdl
CD108	SEMA7A	45.0	bdl
CD138	SDC1	78.1	bdl
CD141	THBD	14.5	bdl
CD146	MCAM	99.8	bdl
CD171	L1CAM	28.2	bdl
CD133	PROM1	71.3	bdl
CD13	ANPEP	bdl	100
CD26	DPP4	bdl	5.9
CD42A	GP9	bdl	13.8
CD42B	GP1BA	bdl	29.2
CD49B	ITGA2	bdl	94.7
CD54	ICAM1	bdl	28.5
CD62E	SELE	bdl	3.3
CD95	FAS	bdl	98.1
CD91	LRP1	bdl	22.1
CD99R	MIC2 receptor	bdl	4.7
CD130	IL6ST	bdl	9.3
CD140A	PDGFRA	bdl	93.0
CD140B	PDGFRB	bdl	49.1
CD142	F3	bdl	1.8
CD166	ALCAM	bdl	79.6
CD227	MUC1	bdl	93.3
SSEA4	SSEA4	bdl	16.8
CD243	ABCB1	2.9	4.1
CD9	CD9	80.2	99.3
CD47	CD47	24.5	98.3
CD49C	ITGA3	29.0	99.7
CD51/61	CD51/61	43.9	96.5
CD55	DAF	60.7	99.8
CD61	ITGB3	1.9	53.8
CD77	A4GALT	7.9	62
CD99	MIC2	23.7	89.3
β-2 microglobulin	B2MICRO	10.8	98.3
EGFR	EGFR	66.5	94.8
HLAABC	HLAABC	35.8	99.8
CD49F	ITGA6	12.2	60
CD340	ERBB2	75.1	82.3
CD221	IGF1R	39.0	77.2
CD24	CD24	13.8	5
CD97	TM7LN1	13.0	4.9
CD56	NCAM1	99.3	18.6
CD165	CD165	98.6	3.9
CD271	NGFR	84.5	12.4
MICA,MICB	MICA,MICB	95.5	2.5
CD164	CD164	37.1	83.5

bdl: below detection limit.

open the way for the development of new targeted therapies for malignant tumors [9–17].

The revelation of a subpopulation of stem-like cells in OS dates back to 2005 by Gibbs et al. [18], after that several research groups addressed their studies on isolation

and identification of OS stem cells using various methods [19–24].

Recently, Di Fiore et al. induced the selection of a cancer stem-like population from the MG63 OS cell line. This new cell line has been named 3-aminobenzamide(AB)-OS since it has been selected and stabilized by treating human OS MG63 cells with 3-AB, a potent competitive inhibitor of poly(ADP-ribose)- polymerase, for about 100 days [25].

The 3AB-OS is a stable and immortalized CSC line that represents the stem component of MG63 parental cell line. Differently from MG63 cells, 3AB-OS cells can grow unlimitedly without losing their proliferative potential [25]. They showed a high drug efflux capacity dependent on adenosine triphosphate binding-cassette G2 transporters. 3AB-OS showed a strong positivity for the stem cell marker CD133, which was almost immeasurable in MG63 cells [25]. Moreover 3AB-OS cells were much less committed to osteogenic and adipogenic differentiation than MG63 cells and displayed a high expression of the genes required for maintaining stem cell state (Octamer-binding transcription factor 3/4, human telomerase reverse transcriptase, nucleostemin, Nanog) and for inhibiting apoptosis (hypoxia-inducible factor-1a, B cell lymphoma-2, and survivin) [25]. Gene expression profile of 3AB-OS in comparison with MG63 revealed the differential regulation of 196 genes involved in important pathways connected to tumorigenesis and stemness, namely Wnt, Notch, Hedgehog, and extracellular signal-regulated kinase (ERK)1/2 (p44/42 mitogen-activated protein kinases, MAPK) signaling [26]. The 3AB-OS cells were highly tumorigenic in mice and tumors that they formed expressed, in a first time, high levels of pAKT, β1-integrin, and pFAK, nuclear β-catenin, c-mycelocytomatosis oncogene cellular homolog, cyclin D2, along with high levels of anti-apoptotic proteins such as B cell lymphoma-2 [27]. Engrafted tumor cells also showed multilineage commitment with matrigel particularly favoring the mesenchymal lineage. Concomitantly, many blood vessels and muscle fibers appeared in the tumor mass [27].

To better characterize the biochemical phenotype of 3AB-OS CSCs, we have analyzed their specific surface proteome profile in comparison with the parental cell line MG63. We performed a high-throughput immunophenotype screening of the two cell lines using an antibody array (Lyoplate[®], Becton Dickinson, Franklin Lakes, NJ, USA) containing quite all “cluster of differentiation” (CD) surface molecules along with other surface antigens associated with stem cells phenotype (242 different specificities), moreover we added an other three antigens lacking in the original array (e.g. CD133, CD324, CD66c). Cells were grown in DMEM supplemented with 10% FBS and 2% L-glutamine at a concentration of 20×10^3 cells/cm². When they reached confluence, cells were detached from culture flasks by trypsin treatment and washed with PBS to be stained. All primary antibodies were lyophilized and allocated into three 96-well plates. Antibodies were reconstituted as described by original datasheet and added to polystyrene tubes containing 100×10^3 cells each for both 3AB-OS and MG63 cell lines. Cells were incubated for 1 h at




Figure 2. (A) PAK (p21-activated kinase) and PTEN (phosphatase and tensin homologue deleted on chromosome 10) pathways. Some of the proteins in the network “cell-to-cell signaling and interaction and inflammatory response” are associated with PAK (blue) and PTEN (red) canonical pathways. Molecules we identified differentially expressed are in green while those in orange were added by IPA network analysis. ERK1/2 (MAPK) is one of the central nodes of both PAK and PTEN pathways. (B) ERK1/2 (MAPK) protein expression level and phosphorylation status. Western blotting analysis and densitometric measurements of protein lysates of 3AB-OS and MG63 cells. Proteins were separated on 4–15% SDS-PAGE and immunoblotted with specific antibodies. The analyses were performed on three independent samples; the results are shown as mean \pm SD.

therapeutic approaches. In fact, surface protein profiling is a key step in the screening for new therapeutic targets; moreover surface antigens are suitable for cancer cell targeted monoclonal antibodies-based therapies.

This work was supported by grant from the Italian Association for Cancer Research AIRC (grant 10737 to professor Del Vecchio).

The authors have declared no conflict of interest.

References

- Picci, P., Osteosarcoma (osteogenic sarcoma). *Orphanet. J. Rare Dis.* 2007, 2, 6–10.
- Ottaviani, G., Jaffe, N., The epidemiology of osteosarcoma. *N. Cancer Treat Res.* 2009, 152, 3–13.
- Tang, N., Song, W. X., Luo, J., Haydon, R. C. et al., Osteosarcoma development and stem cell differentiation. *Clin. Orthop. Relat. Res.* 2008, 466, 2114–2130.
- Caudill, J. S., Arndt, C. A., Diagnosis and management of bone malignancy in adolescence. *Adolesc. Med. State Art. Rev.* 2007, 18, 62–78.
- Li, J. P., Liu, L. H., Li, J., Li, H. et al., Microarray expression profile of long noncoding RNAs in human osteosarcoma. *Biochem. Biophys. Res. Commun.* 2013, 433, 200–206.
- Clarke, M. F., Dick, J. E., Dirks, P. B., Eaves, C. J. et al., Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. *Cancer Res.* 2006, 66, 9339–9344.
- Dalerba, P., Cho, R. W., Clarke, M. F., Cancer stem cells: models and concepts. *Annu. Rev. Med.* 2007, 58, 267–284.
- Shibata, M., Shen, M. M., The roots of cancer: stem cells and the basis for tumor heterogeneity. *Bioessays* 2013, 35, 253–260.
- Corbo, C., Orrù, S., Gemei, M., Di Noto, R. et al., Protein cross-talk in CD133+ colon cancer cells indicates activation of the Wnt pathway and upregulation of SRp20 that is potentially involved in tumorigenicity. *Proteomics* 2012, 12, 2045–2059.
- Gemei, M., Mirabelli, P., Di Noto, R., Corbo, C. et al., CD66c is a novel marker for colorectal cancer stem cell isolation, and its silencing halts tumor growth in vivo. *Cancer* 2013, 119, 729–738.
- Maitland, N. J., Collins, A. T., Prostate cancer stem cells: a new target for therapy. *J. Clin. Oncol.* 2008, 26, 2862–2870.

- [12] Al-Hajj, M., Clarke, M. F., Self-renewal and solid tumor stem cells. *Oncogene* 2004, 23, 7274–7282.
- [13] Eramo, A., Lotti, F., Sette, G., Pilozi, E. et al., Identification and expansion of the tumorigenic lung cancer stem cell population. *Cell Death Differ.* 2008, 15, 504–514.
- [14] O' Brien, C. A., Pollett, A., Gallinger, S., Dick, J. E. et al., A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. *Nature* 2007, 445, 106–110.
- [15] Hu, Y., Yu, X., Liu, S., Liu, S., Cancer stem cells: a shifting subpopulation of cells with stemness? *Med. Hypotheses* 2013, 80, 649–655.
- [16] Zhang, H., Li, S., Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells. *Protein Cell* 2013, 4, 186–96.
- [17] Qian, X., Wagner, S., Ma, C., Klussmann, J. P. et al., ALDH1-positive cancer stem-like cells are enriched in nodal metastases of oropharyngeal squamous cell carcinoma independent of HPV status. *Oncol. Rep.* 2013, 29, 1777–1784.
- [18] Gibbs, P. C., Kukekov, V. G., Reith, J. D., Tchigrinova, O. et al., Stem-like cells in bone sarcomas: Implications for tumorigenesis. *Neoplasia* 2005, 7, 967–976.
- [19] Liu, B., Ma, W., Jha, R. K., Gurung, K., Cancer stem cells in osteosarcoma: recent progress and perspective. *Acta Oncol.* 2011, 50, 1142–1150.
- [20] Martins-Neves, S. R., Lopes, Á. O., do Carmo, A., Paiva, A. A. et al., Therapeutic implications of an enriched cancer stem-like cell population in a human osteosarcoma cell line. *BMC Cancer* 2012, 12, 139–155.
- [21] Wang, L., Park, P., Zhang, H., La Marca, F. et al., BMP-2 inhibits the tumorigenicity of cancer stem cells in human osteosarcoma OS99-1 cell line. *Cancer Biol. Ther.* 2011, 11, 457–463.
- [22] Gong, C., Liao, H., Wang, J., Lin, Y. et al., LY294002 induces G0/G1 cell cycle arrest and apoptosis of cancer stem-like cells from human osteosarcoma via down-regulation of PI3K activity. *Asian Pac. J. Cancer Prev.* 2012, 13, 3103–3107.
- [23] Zhang, H., Wu, H., Zheng, J., Yu, P. et al., Transforming growth factor β 1 signal is crucial for dedifferentiation of cancer cells to cancer stem cells in osteosarcoma. *Stem Cells* 2013, 31, 433–446.
- [24] Liu, B., Ma, W., Jha, R. K., Gurung, K., Cancer stem cells in osteosarcoma: recent progress and perspective. *Acta Oncologica* 2011, 50, 1142–1150.
- [25] Di Fiore, R., Santulli, A., Ferrante, R. D., Giuliano, M. et al., Identification and expansion of human osteosarcoma-cancer-stem cells by long-term 3-aminobenzamide treatment. *J. Cell Physiol.* 2009, 219, 301–313.
- [26] Di Fiore, R., Fanale, D., Drago-Ferrante, R., Chiaradonna, F. et al., Genetic and molecular characterization of the human osteosarcoma 3AB-OS cancer stem cell line: a possible model for studying osteosarcoma origin and stemness. *J. Cell Physiol.* 2013, 228, 1189–1201.
- [27] Di Fiore, R., Guercio, A., Puleio, R., Di Marco, P. et al., Modeling human osteosarcoma in mice through 3AB-OS cancer stem cell xenografts. *J. Cell Biochem.* 2012, 113, 3380–3392.
- [28] Caterino, M., Corbo, C., Imperlini, E., Armiraglio, M. et al., Differential proteomics analysis in human cells subjected to ribosomal stress. *Proteomics* 2013, 13, 1220–1227.
- [29] Roberts, P. J., Der, C. J., Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. *Oncogene* 2007, 26, 3291–3310.